BioSpace News Archive

POINT Biopharma Global Inc. today announced financial results for the first quarter ended March 31, 2023 and provided a business update.

Illumina, a global leader in DNA sequencing and array-based technologies, issued a shareholder letter outlining the purpose-built mix of skills Illumina’s nominees bring to the Board compared to Carl Icahn’s unqualified associates, each of whom lack relevant experience and independence.

Thorne HealthTech, Inc. (“Thorne”) (NASDAQ: THRN), a leader in delivering innovative solutions for a personalized approach to health and wellness, announced today that it is entering into a research and development partnership agreement with Arome Science, a leader in metabolomics, to develop a next-generation metabolomics test.

Dante Genomics, a global leader in genomics and precision medicine, today announced a free, initial feature of its platform agnostic proprietary B2B software to automatically turn FASTQ files to VCF files at no charge as an introduction to its AVANTI Software, demonstrating the broad scalability of its interpretation software to benefit sequencing labs of all sizes around the world.

Elevation Oncology, Inc. (Nasdaq: ELEV), an innovative oncology company focused on the discovery and development of selective cancer therapies to treat patients across a range of solid tumors with significant unmet medical needs, today announced financial results for the quarter ended March 31, 2023, and highlighted recent business achievements.

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, today reported financial results for the first quarter ended March 31, 2023 and provided a corporate update.

Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”, “Company”), a targeted oncology company forging new territory in patient-directed cancer treatment, today announced financial results for the first quarter ended March 31, 2023.

Pfizer Inc. announced that its wholly owned subsidiary, Pfizer Investment Enterprises Pte. Ltd., has commenced a multi-series offering of senior unsecured notes.

Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concerned with retinal health and maintaining better vision longer, today announced financial results for the first quarter of 2023.

Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today reported its financial results for the first quarter of 2023, its recent business highlights, and a preview of select anticipated milestones.